_______________________________________

FREE Daily Stock Alerts From CRWEWallStreet.com

_______________________________________

TAMPA, Fla.–(CRWENEWSWIRE)–PanGenex Corporation (Pink Sheets: PGCX - News) (“PanGenex” or “the Company”) announced that due to promising pre-clinical results from its clinical trial at the Cardiovascular Institute of the South (http://www.cardio.com/site1.php), the Company will extend its trial to two additional sites.

The Company initiated a 100 patient, placebo based, double blind clinical trial at the CardioVascular Institute of the South. Early results with only a handful of patients have encouraged the Company to expand this trial.

The clinical trial involves a protocol to test its product Calci-CLEAR, a two part system designed to cleanse and remove calcium deposits from soft tissues such as veins and arteries. The study entails baseline coronary arterial calcium (CAC) scans, bone mineral density scans (DXA), and normal blood lipid and inflammatory markers. Under the protocol, patients are screened and then placed on the product for a period of 5 months. Following the study duration, follow up CAC, DXA, and lab tests are collected. Dr. Peter Fail, the principle investigator for the trial, indicated that one patient experienced a greater than 50% reduction in CAC score following the 5 months of the study.

The results are not statistically significant due to the few completed participants; however the outcome was significant enough to interest two prominent cardiologists and advisory board members to the Company to initiate trials at their respective clinics.

Steve Yakubov, Medical Director of the MidWest Cardiology Research Foundation and Dr. Mark Turco, Cardiovascular Consultants, PA are both preparing to initiate the clinical protocols at their sites.

“The data is slight, however, there is no other natural product available to my knowledge that has this significant of an effect on CAC scores…and to see these types of results is truly exciting.” stated PanGenex Director Dr. Ronald Caputo.

About PanGenex Corporation:

PanGenex is a publicly traded corporation (PINK SHEETS: PGCX.PK) and pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceutical and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.

Disclaimer:

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements,” which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks” or “will.” Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things: (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contact:

Bulova Technologies Group, Inc.
Beverly Mercer, 727-451-6560
or
PanGenex Corporation
Mindy Rippeto, 813-623-5268
investor@pangenex.com

Source: PanGenex Corporation

************Advertisement************

************************************

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations.